Analysis of 135,000+ medical records shows the novel coronavirus hits hardest among teens, children with diabetes or cancer, lower-income families, and Black, Latin and Asian groups. In the most comprehensive analysis to date of U.S. children tested and treated for COVID-19, an organization representing seven of the nation’s largest pediatric medical centers reports that some
Combining Machine Learning with Cell Engineering, Scientists Can Design ‘Living Medicines’ that Precisely Target Tumors Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research. In two new papers, scientists at UC San Francisco and Princeton University present complementary strategies to crack this problem with “smart”
Hundreds of trials are under way, 3 CAR T-cell therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma Research on chimeric antigen receptor (CAR) T-cell therapies has exploded since
Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled trials. In this paper researchers of the Clinical Pharmacology Section, Hospital Italiano de Buenos Aires, Juan D. Perón, Buenos Aires, Argentina as
Discovery represents a major milestone for regenerative medicine that could help more people benefit from stem cell therapy. Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy—a scientific first and a major advance for the field of regenerative medicine. The
As of September, the vast majority of Americans did not have coronavirus antibodies, according to a new study published in JAMA Internal Medicine. These data matter as the coronavirus spreads rapidly throughout most of the country, most people remain vulnerable to it. Across the U.S., the portion of states’ populations with detectable antibodies ranged from less
The NIAID-sponsored trial will enroll up to 1,500 patients at approximately 100 sites in the United States and other countries. Participants will be assigned at random to one of two treatment arms of equal size. One group will receive both dexamethasone, a corticosteroid available as a generic drug, and remdesivir, a broad-spectrum antiviral discovered and
COVID-19 caused by SARS-COV2 infection can lead to multi-organ injuries and significant mortality in severe and critical patients, especially among those individuals with type 2 diabetes (T2D) as a comorbidity. While attenuated mortality was observed with aggressive glucose control, it was unclear whether therapeutic regiments including insulin treatment was beneficial for patients with COVID-19 and
The SARS-CoV-2 virus is causing a global pandemic and cases continue to rise. Most infected individuals experience mildly symptomatic coronavirus disease 2019 (COVID-19), but it is unknown whether this can induce persistent immune memory that could contribute to immunity. In this paper, published on Cell, it’s performed a longitudinal assessment of individuals recovered from mild
Early reports indicated that in COVID-19 may be associated with coagulation dysfunction. Studies have reported varying rates of thromboembolism. In this paper, the Authors searched PubMed, Cochrane and Embase for systematic reviews and meta-analyses evaluating thromboembolism rates in COVID-19 published until June 12, 2020. The search terms were “COVID-19”, “SARS-CoV-2” or “novel coronavirus” and “venous
